Clincal, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis.

Programmed cell death (apoptosis) of activated lymphocytes is critical to immune homeostasis. The cell surface protein Fas (CD95) and its ligand play a pivotal role in regulating lymphocyte apoptosis, and defective expression of either Fas or Fas ligand results in marked over accumulation of mature lymphocytes and autoimmune disease in mice. The results of recent studies suggest that defective lymphocyte apoptosis caused by mutations of the Fas gene can result in a severe autoimmune lymphoproliferative syndrome (ALPS) in humans. To define the clinical, genetic, and immunologic spectrum of ALPS, 9 patients and their families were extensively evaluated with routine clinical studies, lymphocyte phenotyping, genotyping, and in vitro assays for lymphocyte apoptosis. Individual patients were followed up for 3 months to 6 years. ALPS was identified in 9 unrelated children as manifested by moderate to massive splenomegaly and lymphadenopathy, hypergammaglobulinemia, autoimmunity, B-cell lymphocytosis, and the expansion of an unusual population of CD4- CD8- T cells that express the alpha/beta T-cell receptor (TCR). All patients showed defective lymphocyte apoptosis in vitro. Heterozygous mutations of the Fas gene were detected in 8 patients. One ALPS patient lacked a Fas gene mutation. Healthy relatives with Fas mutations were identified in 7 of 8 ALPS kindreds. These relatives also showed in vitro abnormalities of Fas-mediated lymphocyte apoptosis, but clinical features of ALPS were not present in the vast majority of these individuals. ALPS is a unique clinical syndrome in which in vitro abnormalities of lymphocyte apoptosis are associated with abnormal lymphoproliferation and autoimmunity. These findings provide evidence that apoptosis of activated lymphocytes is an important mechanism for maintaining immunologic homeostasis and self-tolerance in humans. Fas gene mutations account for impaired lymphocyte apoptosis in only a subset of patients with ALPS.

[1]  M. Lenardo.  Fas and the art of lymphocyte maintenance , 1996, The Journal of experimental medicine.

[2]  L. Baum,et al.  Apoptosis of T cells mediated by galectin-1 , 1995, Nature.

[3]  J. Banchereau,et al.  Fas ligation induces apoptosis of CD40-activated human B lymphocytes , 1995, The Journal of experimental medicine.

[4]  P. Krammer,et al.  CD40 ligation induces Apo-1/Fas expression on human B lymphocytes and facilitates apoptosis through the Apo-1/Fas pathway , 1995, The Journal of experimental medicine.

[5]  M. Lenardo,et al.  Induction of apoptosis in mature T cells by tumour necrosis factor , 1995, Nature.

[6]  Mark M. Davis,et al.  CD95 (Fas)-dependent elimination of self-reactive B cells upon interaction with CD4+T cells , 1995, Nature.

[7]  Warren Strober,et al.  Dominant interfering fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome , 1995, Cell.

[8]  F. Rieux-Laucat,et al.  Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. , 1995, Science.

[9]  P. Leder,et al.  RIP: A novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death , 1995, Cell.

[10]  D. Goeddel,et al.  The TNF receptor 1-associated protein TRADD signals cell death and NF-κB activation , 1995, Cell.

[11]  T. Giese,et al.  In CD8+ T cell-deficient lpr/lpr mice, CD4+B220+ and CD4+B220- T cells replace B220+ double-negative T cells as the predominant populations in enlarged lymph nodes. , 1995, Journal of immunology.

[12]  S. Nagata,et al.  Involvement of an ICE-like protease in Fas-mediated apoptosis , 1995, Nature.

[13]  W. Fiers,et al.  Requirement of an ICE/CED-3 protease for Fas/APO-1-mediated apoptosis , 1995, Nature.

[14]  J. Camonis,et al.  A Novel Protein That Interacts with the Death Domain of Fas/APO1 Contains a Sequence Motif Related to the Death Domain (*) , 1995, The Journal of Biological Chemistry.

[15]  S. Nagata,et al.  The Fas death factor , 1995, Science.

[16]  S. Ju,et al.  Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation , 1995, Nature.

[17]  D. Goeddel,et al.  The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation. , 1995, Cell.

[18]  F. Ramsdell,et al.  gld/gld mice are unable to express a functional ligand for Fas , 1994, European journal of immunology.

[19]  N. Jenkins,et al.  Generalized lymphoproliferative disease in mice, caused by a point mutation in the fas ligand , 1994, Cell.

[20]  C. Weaver,et al.  Mature T cells of autoimmune lpr/lpr mice have a defect in antigen-stimulated suicide. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[21]  E. Jaffe,et al.  A novel lymphoproliferative/autoimmune syndrome resembling murine lpr/gld disease. , 1992, The Journal of clinical investigation.

[22]  N. Copeland,et al.  Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis , 1992, Nature.

[23]  M. Lenardo.  lnterleukin-2 programs mouse αβ T lymphocytes for apoptosis , 1991, Nature.

[24]  R. Eisenberg,et al.  Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. , 1991, Annual review of immunology.

[25]  M. Lenardo.  Interleukin-2 programs mouse alpha beta T lymphocytes for apoptosis. , 1991, Nature.

[26]  C. Martínez-A,et al.  Recovery from autoimmunity of MRL/lpr mice after infection with an interleukin-2/vaccinia recombinant virus , 1990, Nature.

[27]  G. Tsokos,et al.  T cell receptor alpha/beta expressing double-negative (CD4-/CD8-) and CD4+ T helper cells in humans augment the production of pathogenic anti-DNA autoantibodies associated with lupus nephritis. , 1989, Journal of immunology.

[28]  A. Steinberg,et al.  CS-A therapy in MRL-lpr/lpr mice: amelioration of immunopathology despite autoantibody production. , 1987, Journal of immunology.

[29]  M. Toribio,et al.  Interleukin 2 promotes growth and cytolytic activity in human T3+4-8- thymocytes. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[30]  H Stein,et al.  Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. , 1984, Journal of immunology.